Dolutegravir Sodium Patent Expiration
Dolutegravir Sodium was first introduced by Viiv Healthcare Co
Dolutegravir Sodium Patents
Given below is the list of patents protecting Dolutegravir Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tivicay |
US9242986 (Pediatric) | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Jun 08, 2030 | Viiv Hlthcare |
| Tivicay Pd |
US9242986 (Pediatric) | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Jun 08, 2030 | Viiv Hlthcare |
| Tivicay | US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Dec 08, 2029 | Viiv Hlthcare |
| Tivicay Pd | US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Dec 08, 2029 | Viiv Hlthcare |
| Tivicay |
US8129385 (Pediatric) | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Apr 05, 2028 | Viiv Hlthcare |
| Tivicay Pd |
US8129385 (Pediatric) | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Apr 05, 2028 | Viiv Hlthcare |
| Tivicay | US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Oct 05, 2027 | Viiv Hlthcare |
| Tivicay Pd | US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Oct 05, 2027 | Viiv Hlthcare |
Dolutegravir Sodium's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List